Dataset Information

Surfactant Protein D promotes the inhibition of tumor growth and metastatic progression with a potential for therapeutic intervention

ABSTRACT: Pulmonary surfactant protein D (SP-D) is an endogenous innate immune factor known to be involved in several immune related diseases and has also been linked to lung adenocarcinoma cell growth. By analyzing single-cell, bulk, and spatial transcriptomics of human clinical samples, we have demonstrated significantly reduced expression in lung cancer cells compared to healthy cells, along with a distinct localization of SP-D expression in stromal areas adjacent to the tumor cells and at the periphery. Interestingly, a near-complete loss of SP-D expression was observed in metastatic tissue, suggesting its association with a more aggressive and metastatic phenotype. In this context, we show that SP-D re-expression in A549 adenocarcinoma cell line significantly decreased tumor growth and spontaneous metastasis formation in vivo and furthermore, that intranasal administration of recombinant SP-D signicantly reduced lung tumor burden. Mechanistically, we demonstrated that SP-D supresses interleukin 4 (IL4)/IL13 signaling pathways. Intriguingly, our data revealed that recombinant SP-D binds directly to the IL4 receptor, leading to the effective inhibition of the IL4 signaling pathway. Collectively, these findings demonstrate that SP-D acts as a tumor supressor inhibiting both tumor growth and metastatic progression potentially through blokage of the IL4/STAT6 signaling pathway. This provides a rationale of SP-D as a promising therapeutic agent for modulating crucial signaling pathways involved in cancer development and progression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249805 | GEO | 2025/12/31

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:TIMP2 inhibits metalloproteinase activity and possesses metalloproteinase-independent functions that regulate cell growth, invasion, and gene expression. Although mounting evidence suggests TIMP2 can reduce tumor burden and metastasis the demonstration of these effects using in vivo tumor models are lacking. In this study, we examine the effects of functional mutation of Timp2 and administration of recombinant TIMP2 in models of both orthotopic and heterotopic murine lung cancer using the syngeneic Lewis Lung carcinoma cells (LL/2-luc2). Mice harboring a functional mutation of TIMP2 (mT2) display a marked increase in tumor growth and mortality, enhanced tumor micro-vasculature, and greater infiltration of myeloid-derived cells compared to wt mice, suggesting that reduced TIMP2 function results in enhanced presence of pro-tumorigenic, immunosuppressive myeloid cells. Treatment with recombinant TIMP2 reduced primary tumor growth in both genotypes. Transcriptional profiling of lung tissues from non-tumor-bearing mice reveals minimal changes in mice. However, orthotopic, lung tumor-bearing mice demonstrate significant changes in gene expression that are genotype-dependent. In tumor-bearing wt mice TIMP2-treatment reduced the expression of upstream oncogenic mediators. In comparison, treatment of mT2 mice resulted in an immunomodulatory phenotype, as suggested by enhanced activity of Il4, Il2, and Ifng. A heterotopic model of LL/2 generating metastatic pulmonary tumors demonstrated that daily administration of recombinant TIMP2, while also reducing primary tumor growth, significantly altered transcriptional profiles in the lungs of wt mice, suggesting modification of the metastatic niche. These changes result in the downregulation of cell-stress responses, as evidenced by reduced expression of heat shock proteins. In summary, we describe how TIMP2 exerts novel, anti-tumor effects in a murine model of lung cancer and that rTIMP2 treatment supports a normalizing effect on the tumor microenvironment. These findings support the concept that TIMP2 displays homeostatic functions to reverse cell stress signaling in addition to inhibition of metalloproteinases.

Project description:Project 1: The deregulation of the actin cytoskeleton has been extensively studied in metastatic dissemination. However, the post-dissemination role of the actin cytoskeleton dysregulation is poorly understood. Here we report that fascin, an actin-bundling protein, promotes lung cancer metastatic colonization by augmenting metabolic stress resistance and mitochondrial OXPHOS. Fascin is directly recruited to mitochondria under metabolic stress to stabilize mitochondrial actin filaments (mtF-actin). Using unbiased metabolomics and proteomics approaches, we discovered that fascin-mediated mtF-actin remodeling promotes mitochondrial OXPHOS by increasing the biogenesis of respiratory Complex I. Mechanistically, fascin and mtF-actin controls the homeostasis of mtDNA to promote mitochondrial OXPHOS. The disruption of mtFactin abrogates fascin-mediated lung cancer metastasis. Conversely, restoration of mitochondrial respiration using yeast NDI1 in fascin depleted cancer cells is able to rescue lung metastasis. Our findings indicate that the dysregulated actin cytoskeleton in metastatic lung cancer could be targeted to rewire mitochondrial metabolism and to prevent metastatic recurrence. Project 2: There is a pool of mitochondrial dNTP in the cell maintained by the mitochondrial deoxynucleoside salvage pathway and dedicated for the mtDNA homeostasis in slow-cycling and post-mitotic cells. The role of the mitochondrial deoxynucleoside salvage pathway in tumor initiation and progression is poorly understood. Here, we investigated the role of the mitochondrial deoxyguanosine kinase (DGUOK), a rate-limiting enzyme in the mitochondrial deoxynucleoside salvage pathway, in the self-renewal of lung adenocarcinoma cancer stem-like cells (CSC). Our data support that DGUOK overexpression strongly correlates with cancer progression and patient survival. The depletion of DGUOK robustly inhibited lung adenocarcinoma tumor growth, metastasis and CSC self-renewal. Mechanistically, DGUOK is required for the biogenesis of respiratory Complex I and mitochondrial OXPHOS, which in turn regulates CSC self-renewal through AMPK-YAP1 signaling. The restoration of mitochondrial OXPHOS in DGUOK depleted lung cancer cells using NDI1, a single subunit yeast NADH : ubiquinone oxidoreductase, was able to rescue AMPK-YAP1 signaling and CSC stemness. Genetic targeting of DGUOK using doxycycline-inducible CRISPR/Cas9 was able to markedly induce tumor regression. Our findings reveal a novel role for mitochondrial dNTP metabolism in lung cancer tumor growth and progression, and implicate that the mitochondrial deoxynucleotide salvage pathway could be potentially targeted to prevent CSC-mediated therapy resistance and metastatic recurrence.

Dataset Information

Surfactant Protein D promotes the inhibition of tumor growth and metastatic progression with a potential for therapeutic intervention

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets